ForeverLabs Logo
0%
ClinicalBloodDiabetes

A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes

PubMed

No alternative intervention strategies match, or even get close to, the clinical outcome achieved in a considerable number of patients treated with autologous stem cell transplantation. We propose that this patient group should be identified, diligently informed and offered the possible benefits of an extended period of insulin-free and burden-free survival,

AI generated image for: A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes

No alternative intervention strategies match, or even get close to, the clinical outcome achieved in a considerable number of patients treated with autologous stem cell transplantation. We propose that this patient group should be identified, diligently informed and offered the possible benefits of an extended period of insulin-free and burden-free survival,

Research Details

Source

PubMed

Publication Date
Categories & Tags
ClinicalBloodDiabetes
View Original Publication

Cite this article: PubMed. "A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes". Published August 11, 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5904498/

Access Original Research

View the complete study and detailed methodology from the original source.

Read Full Study↗
← All Articles← Clinical Articles

You Might Also Like

Explore more articles in this category

AI generated image for: Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial
2 min

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial

OBJECTIVE To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. METHODS We conducted a multicenter, phase II, randomized trial including patients with secondary progressive or relapsing-remitting MS, with a documented increase in the last year on the Expanded Disability Status Scale, in spite of conventional therapy, and presence of one or more gadolinium-enhancing (Gd+) areas. Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosine-arabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by AHSCT or MTX 20 mg every month for 6 months. The primary endpoint was the cumulative number of new T2 lesions in the 4 years following randomization. Secondary endpoints were the cumulative number of Gd+ lesions, relapse rate, and disability progression. Safety and tolerability were also assessed. Twenty-one patients were randomized and 17 had postbaseline evaluable MRI scans. RESULTS AHSCT reduced by 79% the number of new T2 lesions as compared to MTX (rate ratio 0.21, p = 0.00016). It also reduced Gd+ lesions as well as the annualized relapse rate. No difference was found in the progression of disability. CONCLUSION Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints.

Neurology
AI generated image for: Effect of aging on stem cells
1 min

Effect of aging on stem cells

As we age, stem cells lose efficacy and ability to heal.

NIH
AI generated image for: Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer's disease
1 min

Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer's disease

Intravenous transplantation of bone marrow-derived mononuclear cells (BMMCs) successfully improved cognitive function and prevented neurodegeneration in two different Alzheimer's disease mouse models.

PubMed